Navigation Links
Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
Date:6/2/2008

trial for ANA773 in cancer patients in February and this study of ANA598 underway, Anadys is now focused on achieving important clinical milestones in both programs."

About ANA598

ANA598 is a highly potent and selective inhibitor of HCV genotypes 1a and 1b NS5b RNA polymerases (IC50 < 1 nM) and of HCV replication in cell culture (EC50 values for genotypes 1b and 1a replicons are 3 and 50 nM, respectively). ANA598 has been well-tolerated in all preclinical studies, including 28-day GLP toxicology studies, and was selected as a development candidate in June 2007.

Clinical Need and Market Opportunity in HCV Infection

Chronic hepatitis C virus (HCV) infection is a serious public health concern affecting approximately 2.7 million people in the United States and approximately 170 million people worldwide. HCV causes inflammation of the liver, which may lead to fibrosis and cirrhosis, liver cancer, and ultimately, liver failure. Cirrhosis of the liver resulting from chronic HCV infection is the leading indication for liver transplantation in the U.S. Due to the asymptomatic nature of HCV infection, it often goes undetected for up to 20 years following initial infection. Each year, 8,000 to 10,000 people in the U.S. die from complications of HCV.

The current standard of care is a combination of pegylated interferon and ribavirin. Inadequate response rates, in particular for patients infected with genotype 1 HCV, along with significant side effects of approved therapy, support the medical need for improved treatment options. It is estimated that fewer than 5% of people with chronic HCV infection living in the U.S. are under treatment today. The majority of infected individuals are unaware of their infection status and the large majority of individuals who know their status do not currently receive drug therapy. There is also a growing number of individuals who have failed interferon-based regimens who may be successfully treated with combi
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 2015  MEI Pharma, Inc. (Nasdaq: MEIP ), an ... for cancer, announced today that Daniel P. Gold , ... inaugural Cantor Fitzgerald Healthcare Conference on Wednesday, July 8, 2015 ... in New York . A live ... . A replay will be available approximately one hour after ...
(Date:7/1/2015)... 2015 Lupin , ... Total Number of MPP Sub-licensees to Fourteen Companies   ... announced the rapid expansion of its network of generic manufacturers ... to develop MPP-licensed antiretrovirals (ARVs). New companies Lupin and Strides ... new HIV medicine the MPP licensed from ViiV Healthcare two ...
(Date:7/1/2015)... SAN DIEGO , July 1, 2015  AVACEN, Inc. ... a second AVACEN patent covering the medical technology platform supporting ... Logo - http://photos.prnewswire.com/prnh/20150630/227364LOGO ... The apparatus and methods patent no. 9,066,781 - Methods And ... devices manufactured by AVACEN and specific methods of use, referred ...
Breaking Medicine Technology:MEI Pharma to Present at Cantor Fitzgerald Healthcare Conference 2The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 2The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 3AVACEN Medical Patent Issued 2
(Date:7/1/2015)... ... July 01, 2015 , ... The ... Levaquin ( http://www.injurybeacon.com/levaquin/lawsuit/ ) has granted the Defendants’ Motion for Summary Judgment. According ... Virginia on June 26th, the Court rejected the Plaintiff’s assertion that one ...
(Date:7/1/2015)... ... July 01, 2015 , ... Ormco Corporation, ... that its fifth annual Smile for a Lifetime Foundation (S4L) fundraising event held ... In addition to supporting S4L in its mission to provide free quality orthodontic ...
(Date:7/1/2015)... ... 01, 2015 , ... Renowned rhinoplasty surgeon and Symposium Chairman, ... Rhinoplasty Symposium . Set for March 6th - 8th, the 2016 meeting will be ... basic training and fundamentals of nasal surgery through the most modern advancements and updates ...
(Date:7/1/2015)... Tenn. (PRWEB) , ... July 01, 2015 , ... The ... held rain or shine Saturday, July 11, 2015, at 6 p.m. in Pugh Bourne ... free and includes pony rides, a petting zoo, an Elvis impersonator, a silent auction ...
(Date:7/1/2015)... ... July 01, 2015 , ... Trevor L. Williams, DMD holds a ... continued at USF earning a Master’s degree in Microbiology. He graduated from the University ... American Dental Association, the Florida Dental Association and the Academy of General Dentistry. Dr. ...
Breaking Medicine News(10 mins):Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 3Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 2Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 3Health News:Dr. Rod J. Rohrich Announces Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Trevor L. Williams, D.M.D. Joins Enlow & Vance Dental Partners in Tampa, Florida 2
... right side, requiring colonoscopy for detection, study says , SUNDAY, May ... as women to have colon polyps and are also more likely ... found. , The researchers also found that the study patients older ... those younger than 60. , Polyps are growths in the large ...
... supports most options, but families driven by need to help, ... -- About one in five children with autism uses alternative ... special diet, a new study finds. , Of 1,212 children ... 17 percent were on special diets. More than half of ...
... ... the economy recovers and national Health Reform is implemented, explore the possible implications for ... ... BMEGateway, the national leader in Independent Evaluation and Review services for over 20 years, ...
... It is well-known that children in foster care are at increased ... who live with relatives other than their birth parents? Children ... child welfare agencies, and little research has been done on this ... MD, and her colleagues, used data from a 2007 national survey ...
... Physicians usually ask children to fast overnight before a cholesterol ... necessary. "Cholesterol testing can be very difficult for families," ... to be presented Sunday, May 2 at the Pediatric Academic ... having to fast, this almost always means the child has ...
... beyond the postpartum period and become a chronic condition, ... of Medicine. The study also finds that symptoms could ... presented May 1 by lead author Carol C. Weitzman, ... Study Center at Yale School at Yale School of ...
Cached Medicine News:Health News:Colon Polyps More Common in Hispanic Men Than Women 2Health News:Parents of Autistic Children Turning to Alternative Treatments 2Health News:Parents of Autistic Children Turning to Alternative Treatments 3Health News:Parents of Autistic Children Turning to Alternative Treatments 4Health News:BMEGateway Announces Insurance Symposium Will Focus on Orthopedic Issues with an All-star Team of Experts Held May 18, 2010 2Health News:BMEGateway Announces Insurance Symposium Will Focus on Orthopedic Issues with an All-star Team of Experts Held May 18, 2010 3Health News:Children living with relatives struggle with physical, mental health issues 2Health News:Children may be able to eat before cholesterol test, study shows 2Health News:Beyond postpartum -- treating depression in mothers of older children 2
The NPB-40 Handheld Pulse Oximeter is both compact and affordable. It is simple to operate, provides spot-check monitoring of SpO 2 and pulse rate, and is compact enough to fit in your pocket....
... handheld oximeter has been converted to the ... now compatible with the entire line of ... Sensor and SoftCare Nonadhesive Sensors. The redesigned ... Nellcor's latest advanced signal processing technology, which ...
... expanding the growing portfolio of OxiMax® ... is a compact, affordable bedside monitor. ... processing technology, it offers reliable operation ... compatible with the complete family of ...
The Model 900 is a new desk top pulse oximeter that was designed for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring. It also incorporates an LCD waveform m...
Medicine Products: